Located in an industrial complex in East Baltimore’s Highlandtown, Baltimore Underground Science Space, popularly known as BUGSS, engages Baltimore community members in open dialogue and “learning through doing” as new biological technologies become more ingrained in our everyday lives.
The Horizon report is based on survey responses from more than 500 industry leaders who provide insight into all corners of the industry. The investigation of cell and gene therapies is proving to be a disruptive space that is reshaping biopharma business models. When cell therapies first went into human testing, Walters said the big question on the minds of the scientists was, “will it work?”
Rockville, Maryland’s American Gene Technologies (AGT) is on a mission to cure HIV. And they just achieved another important milestone in that potentially groundbreaking journey.
In early November 2021, the company announced that the third patient in its first-in-human study for AGT103-T, a cell therapy for HIV, had been dosed with no serious adverse events. This latest milestone achievement moves the company and its team another step closer to curing HIV and making history.
We’re excited to announce this year’s finalists for the second annual 2021 BioBuzz Awards. These awards celebrate the people and companies across our regional community and their efforts and accomplishments to impact human health and build a stronger biotech community.
South Duvall and Sagamore Ventures Team Up to Bring High-End Lab Space to Baltimore’s Port Covington
Last week South Duvall and Sagamore Ventures announced that they have formed a partnership to bring more than 100,000 square feet of high-end laboratory space to City Garage in Baltimore’s Port Covington over the next ten years. Approximately 75,000 square feet of space is set to be delivered in the next year alone.
REGENXBIO and Solid Biosciences Take Aim at Rare Diseases with AAV Gene Therapies via New Pathway Development Consortium
Rare disease specialist REGENXBIO is partnering with Solid Biosciences to advance AAV gene therapies for rare diseases through an accelerated approval pathway with the U.S. Food and Drug Administration.
Secretary of Commerce tours new I-270 Innovation Labs, flexible lab space meeting critical industry need
From left to right: Kelly Shultz – Secretary of Commerce, State of Maryland; Luis Rugeles – Co-founder & CEO, I-270 Innovation Labs; and Doug Bane – Co-founder & COO, I-270 Innovation Labs.
The growing life sciences ecosystem in Maryland has become a shining star in the BioHealth Capital Region. The region has seen explosive growth driven by billions of federal dollars aimed at R&D efforts to combat the COVID-19 threat. And that continued growth has become a magnet for a robust supply of life sciences talent that will continue to shape the future of the state and region.
Alzheimer’s disease has been one of the toughest disorders for drugmakers to tackle, with multiple trial failures year after year. Companies have exhausted resources as they examined different pathways in what have mostly been futile attempts to develop a therapeutic to halt or delay the onset of this devastating neurodegenerative disease.
Milken Institute Report Highlights How Maryland is Growing one of the Nation’s Strongest Life Science Ecosystems
Home to an array of renowned universities, federal labs, and government resources, it’s no surprise that the globally renowned Milken Institute found that Maryland “has one of the nation’s strongest life sciences industries,” according to its recent report.
It’s clear that Maryland’s efforts to grow its recognition as a life sciences/biotech hub have paid off. However, there is still more work to be done in order for Maryland’s R&D growth trajectory to keep up with other leading hubs such as Massachusetts and North Carolina.